Skip to content
DataLookout
Menu

NCT07436689

Long-Term Open-Label Extension Study of Oral Levosimendan

StatusEnrolling by Invitation
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Oct 21, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 9 → 14 locations
  2. Notable Eligibility criteria expanded, about 7 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Study sites: 9 to 10
  3. Minor Study sites: 7 to 9v4
  4. Minor Study sites: 5 to 7v3
  5. Minor Start date changed from estimate of Mar 2026 to Mar 13, 2026v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The incidence (i.e., the percentage of patients who experience at least 1 occurrence) of select AE/SAEs
Timeframe: From enrollment through study completion (up to 3 years)

Arms and interventions

TNX-103Experimental

Open-label oral levosimendan 1-3mg

Drugs: TNX-103

Sites

14 sites in 2 countries

United States 13, Canada 1